Skip to main content

Immunome Inc.

IMNM
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001472012

In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 1 sale; 210 institutions reported holding it in 13F filings for Q3 2026, worth $2.58B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 19, 2026
$1.96B
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $334.2K in total
1
13F holdersQ3 2026, +11 vs. previous quarter
210
13F valueReported value at the end of Q3 2026
$2.58B
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$6.94M
−23.2% year over year
Net income, FY2025
-$212.4M
No comparable prior period
Free cash flow, FY2025
-$200.6M
No comparable prior period
Revenue, Q3 FY2026
$0
No comparable prior period

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $212.4M (3060.0% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
16.2M
Shares sold short
Change
−1.11M
−6.4% vs. previous
Days to cover
12.77
At average daily volume

Superinvestors holding IMNM, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding IMNM at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Immunome Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 15, 2026 (view filing)4:30 PM ETSep 114 daysHiggins JackChief Scientific OfficerSSale−13.2K$25.32−$334.2K−16.9%65.0K after10b5-1
Aug 12, 2026 (view filing)5:47 PM ETAug 10-112 daysBarchas IsaacDirectorSSale−72.4K$26.21−$1.90M−100.0%0 after2 lots10b5-1
Aug 12, 2026 (view filing)5:47 PM ETAug 12Same dayBarchas IsaacDirectorSSale−11.0K$27.25−$301.1K−10.7%92.2K after10b5-1
Aug 10, 2026 (view filing)4:10 PM ETAug 6-74 daysBarchas IsaacDirectorSSale−36.1K$26.06−$940.5K−33.3%72.4K after2 lots10b5-1
Aug 6, 2026 (view filing)6:30 PM ETAug 42 daysHorn KinneyCHIEF BUSINESS OFFICERSSale−90.6K$25.09−$2.27M−100.0%0 after10b5-1
Jul 9, 2026 (view filing)5:38 PM ETJul 72 daysHorn KinneyCHIEF BUSINESS OFFICERSSale−1.09K$25.00−$27.3K−100.0%0 after10b5-1
Jul 7, 2026 (view filing)7:02 PM ETJul 6-71 dayBarchas IsaacDirectorSSale−100.0K$24.13−$2.41M−48.0%108.5K after2 lots10b5-1
Jul 7, 2026 (view filing)5:42 PM ETJul 25 daysLechleider RobertChief Medical OfficerSSale−55.0K$22.62−$1.24M−77.7%15.8K after3 lots10b5-1
Jul 2, 2026 (view filing)8:31 PM ETJun 30-Jul 22 daysBarchas IsaacDirectorSSale−201.1K$21.85−$4.39M−49.1%208.5K after3 lots10b5-1
Jun 29, 2026 (view filing)Jun 254 daysLechleider RobertChief Medical OfficerSSale−55.0K$19.85−$1.09M−77.7%15.8K after2 lots10b5-1

Top 10 13F holders, Q3 2026

See all 210 holders

The largest institutional positions in Immunome Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding IMNM in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
T. Rowe Price Investment Management, Inc.20,211,392$434.7M0.31%+534,509+2.7%Added
FMR LLC17,036,641$366.5M0.02%+49,088+0.3%Added
BlackRock, Inc.8,929,024$192.1M0.00%+123,532+1.4%Added
Wellington Management Group LLP6,041,333$129.9M0.02%+831,117+16.0%Added
Driehaus Capital Management LLC4,976,950$107.1M0.74%+630,811+14.5%Added
Vanguard Capital Management LLC4,882,131$105.0M0.00%+330,842+7.3%Added
Primecap Management Co4,644,821$99.9M0.06%+63,390+1.4%Added
State Street Corp4,490,152$96.6M0.00%−1,004,473−18.3%Reduced
Redmile Group, LLC4,363,064$93.8M6.87%−548,526−11.2%Reduced
Enavate Sciences GP, LLC3,613,799$77.7M27.79%00.0%Unchanged

Holders of 5% or more of IMNM

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Immunome Inc..

Largest holders of IMNM from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
T. Rowe Price Investment Management, Inc.13G/A17.40%19.7M shares+2.90 ppfrom 14.50%Nov 14, 20244 filingsAug 14, 2026SEC
FMR LLC13G/A15.00%13.1M shares+7.90 ppfrom 7.10%Feb 9, 20245 filingsOct 7, 2025SEC
Immunome Aggregator, LP13D/A6.00%4.77M shares–Oct 12, 20232 filingsFeb 4, 2025SEC
Wellington Management Group LLP13G5.30%6.04M sharesNewNov 16, 20261 filingNov 16, 2026SEC
Vanguard Capital Management LLC13G5.04%5.73M sharesNewOct 30, 20261 filingOct 30, 2026SEC